Kinnate lays off 70% of employees, shaves pipeline to focus on CDK4 and pan-RAF inhibitor
Kinnate Biopharma has reduced its employee headcount by 70% — leaving just 28 full-time employees — and is “separating” from all employees at its Chinese subsidiary, Kinnjiu Biopharma, as part of cost-saving measures to extend its cash runway into at least the second quarter of 2026.
The California-headquartered cancer company is also changing up its pipeline, focusing on its exarafenib/binimetinib combo, KIN-8741, and its CDK4 selective program. For now, Kinnate will halt development of MEK inhibitor KIN-7136, and “explore strategic alternatives” for its exarafenib monotherapy and FGFR inhibitor KIN-3248.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.